Potential Adverse Effects of COVID19 Vaccines Among Iraqi Population; a Comparison Between the Three Available Vaccines in Iraq; a Retrospective Cross-sectional Study

Overview

Journal Diabetes Metab Syndr

Specialty Endocrinology

Date 2021 Jul 19

PMID 34280733

Citations 62

Authors

Hind B Almufty

Shinah A Mohammed

Arshad M Abdullah

Muayad A Merza

Affiliations

Soon will be listed here.

Abstract

Aims: the objectives of this study are to reveal the potential side effects after taking the covid19 vaccines, associated risk factors with severe side effects, and to compare the three COVID-19 vaccines available in Iraq (Sinopharm, AstraZeneca-Oxford and Pfizer- BioNTech).

Methods: a randomized cross-sectional study was conducted in April 2021. A standardized questionnaire platform was utilized to collect information about the Iraqi population.

Results: 1012 were enrolled in the study, 60.2% were male and 39.8% were female. 84% were symptomatic post vaccination. Young aged participants, females, participants with history of COVID19 infection, those with comorbid diseases and AstraZeneca vaccine receivers were statistically significant risk factors for having adverse reactions post vaccination, P value (0.03, 0.028, 0.007, 0.019 and 0.0001) respectively. Regarding severity of symptoms, most symptoms were mild and moderate. Residency in Kurdistan Region of Iraq and AstraZeneca vaccine were the statistically significant risk factors for getting severe symptoms P value < 0.0001 of both. Females were an associated risk factor for D-dimer elevation P value = 0.05.

Conclusion: fatigue, injection site reactions, fever, myalgia, headache and chills were the most reported side effects. Most symptoms were mild to moderate in term of severity.

Citing Articles

Evaluating the Adverse Effects and Associated Risk Factors of COVID-19 Vaccines Among Healthcare Workers: A Retrospective Study in the Duhok Province, Iraq.

Naqid I Cureus. 2024; 16(10):e71671.

PMID: 39553063 PMC: 11568403. DOI: 10.7759/cureus.71671.

Side Effects of COVID-19 Vaccines in Iraqi Kurdistan: A Population-Based Study.

Naqid I, Mosa A, Hito L, Jamil D, Shukur I, Abdulkareem D Cureus. 2024; 16(10):e71170.

PMID: 39525127 PMC: 11549252. DOI: 10.7759/cureus.71170.

COVID-19 vaccinations and their side effects: a scoping systematic review.

Monadhel H, Abbas A, Mohammed A F1000Res. 2024; 12:604.

PMID: 39512911 PMC: 11541072. DOI: 10.12688/f1000research.134171.2.

Adverse events following COVID-19 vaccination: A comprehensive analysis of spontaneous reporting data in Ghana.

Asare A, Sabblah G, Buabeng R, Alhassan Y, Asamoa-Amoakohene A, Amponsa-Achiano K PLOS Glob Public Health. 2024; 4(9):e0003770.

PMID: 39331603 PMC: 11432875. DOI: 10.1371/journal.pgph.0003770.

Immunogenicity and adverse events of the COVID-19 vaccines in healthy and individuals with autoimmune diseases in an Iranian population.

Hasan-Abad A, Arbabi M, Gilasi H, Motedayyen H Int J Immunopathol Pharmacol. 2024; 38:3946320241239202.

PMID: 38494849 PMC: 10946076. DOI: 10.1177/03946320241239202.

References

Szmyd B, Karuga F, Bartoszek A, Staniecka K, Siwecka N, Bartoszek A . Attitude and Behaviors towards SARS-CoV-2 Vaccination among Healthcare Workers: A Cross-Sectional Study from Poland. Vaccines (Basel). 2021; 9(3). PMC: 8000513. DOI: 10.3390/vaccines9030218. View

Choi W, Cheong H . COVID-19 Vaccination for People with Comorbidities. Infect Chemother. 2021; 53(1):155-158. PMC: 8032917. DOI: 10.3947/ic.2021.0302. View

Dong E, Du H, Gardner L . An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020; 20(5):533-534. PMC: 7159018. DOI: 10.1016/S1473-3099(20)30120-1. View

Nazy I, Sachs U, Arnold D, McKenzie S, Choi P, Althaus K . Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost. 2021; 19(6):1585-1588. PMC: 8250233. DOI: 10.1111/jth.15341. View

Zhu F, Li Y, Guan X, Hou L, Wang W, Li J . Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020; 395(10240):1845-1854. PMC: 7255193. DOI: 10.1016/S0140-6736(20)31208-3. View

Hatmal M, Al-Hatamleh M, Olaimat A, Hatmal M, Alhaj-Qasem D, Olaimat T . Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. Vaccines (Basel). 2021; 9(6). PMC: 8229440. DOI: 10.3390/vaccines9060556. View

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K . Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020; 21(2):181-192. PMC: 7832443. DOI: 10.1016/S1473-3099(20)30843-4. View

Lee E, Cines D, Gernsheimer T, Kessler C, Michel M, Tarantino M . Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol. 2021; 96(5):534-537. PMC: 8014568. DOI: 10.1002/ajh.26132. View

Riad A, Pokorna A, Attia S, Klugarova J, Koscik M, Klugar M . Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J Clin Med. 2021; 10(7). PMC: 8037149. DOI: 10.3390/jcm10071428. View

10.

Di Nisio M, Squizzato A, Rutjes A, Buller H, Zwinderman A, Bossuyt P . Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost. 2006; 5(2):296-304. DOI: 10.1111/j.1538-7836.2007.02328.x. View

11.

Merza M, Abdulah D, Mohammed H, Yones A . Epidemiological Trends of the 2019 Coronavirus Disease in Iraqi Kurdistan. Disaster Med Public Health Prep. 2021; :1-3. PMC: 8193185. DOI: 10.1017/dmp.2021.124. View

12.

Dror A, Eisenbach N, Taiber S, Morozov N, Mizrachi M, Zigron A . Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol. 2020; 35(8):775-779. PMC: 8851308. DOI: 10.1007/s10654-020-00671-y. View

13.

Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z . Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020; 324(10):951-960. PMC: 7426884. DOI: 10.1001/jama.2020.15543. View

14.

Harrison E, Wu J . Vaccine confidence in the time of COVID-19. Eur J Epidemiol. 2020; 35(4):325-330. PMC: 7174145. DOI: 10.1007/s10654-020-00634-3. View

15.

Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P . Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021; 21(7):939-949. PMC: 8078878. DOI: 10.1016/S1473-3099(21)00224-3. View

16.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

17.

Luyten J, Bruyneel L, van Hoek A . Assessing vaccine hesitancy in the UK population using a generalized vaccine hesitancy survey instrument. Vaccine. 2019; 37(18):2494-2501. DOI: 10.1016/j.vaccine.2019.03.041. View

18.

Kaur S, Gupta V . COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020; 288:198114. PMC: 7423510. DOI: 10.1016/j.virusres.2020.198114. View

19.

Rice S, Ferree S, Atanaskova Mesinkovska N, Kourosh A . The art of prevention: COVID-19 vaccine preparedness for the dermatologist. Int J Womens Dermatol. 2021; 7(2):209-212. PMC: 7802521. DOI: 10.1016/j.ijwd.2021.01.007. View

20.

Mallapaty S, Callaway E . What scientists do and don't know about the Oxford-AstraZeneca COVID vaccine. Nature. 2021; 592(7852):15-17. DOI: 10.1038/d41586-021-00785-7. View